All In Biotech

Drug Trial Radar · NCT01345253

GSK1550188 A 52 Week Study of Belimumab Versus Placebo in the Treatment of Subjects With Systemic Lupus Erythematosus (SLE) Located in Northeast Asia

Last checked: Nov 20, 2026Latest source record: Oct 4, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 709 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

709

Actual

Start

May 23, 2011

Primary completion

Sep 15, 2015

Study completion Sep 21, 2018

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
Collaborators
Human Genome Sciences Inc.
First posted
May 2, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of belimumab in addition to standard therapy compared to placebo in subjects in Northeast Asia with systemic lupus erythematosus (SLE) over a 52 week period.

Conditions

  • Systemic Lupus Erythematosus

Interventions

  • BelimumabDrug

    10mg/kg administered intravenously. Dosing at Weeks 0, 2, and 4, then every 4 weeks through Week 48, with a final evaluation at Week 52. All study subjects will receive standard SLE therapies during the study.

  • PlaceboDrug

    Administered intravenously. Dosing at Weeks 0, 2, and 4, and then every 4 weeks through Week 48, with a final evaluation at Week 52. All study subjects will receive standard SLE therapies during the study.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent of Participants Achieving Systemic Lupus Erythematosus (SLE) Responder Index (SRI) Response Rate at Week 52 for Double-blind Phase.Time frame: Week 52

Locations

47 sites in 3 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Beijing, China

  • GSK Investigational Site

    Beijing, China

  • GSK Investigational Site

    Beijing, China

  • GSK Investigational Site

    Chongqing, China

  • GSK Investigational Site

    Shanghai, China

  • GSK Investigational Site

    Shanghai, China

  • GSK Investigational Site

    Shanghai, China

  • GSK Investigational Site

    Shanghai, China

  • GSK Investigational Site

    Tianjin, China

  • GSK Investigational Site

    Hefei, Anhui, China

  • GSK Investigational Site

    Guangzhou, Guangdong, China

  • GSK Investigational Site

    Guangzhou, Guangdong, China

  • GSK Investigational Site

    Guangzhou, Guangdong, China

  • GSK Investigational Site

    Harbin, Heilongjiang, China

  • GSK Investigational Site

    Changsha, Hunan, China

  • GSK Investigational Site

    Changsha, Hunan, China

  • GSK Investigational Site

    Nanjing, Jiangsu, China

  • GSK Investigational Site

    Suzhou, Jiangsu, China

  • GSK Investigational Site

    Xi'an, Shaanxi, China

  • GSK Investigational Site

    Jinan, Shandong, China

  • GSK Investigational Site

    Chengdu, Sichuan, China

  • GSK Investigational Site

    Kunming, Yunnan, China

  • GSK Investigational Site

    Hangzhou, Zhejiang, China

  • GSK Investigational Site

    Chiba, Japan

  • GSK Investigational Site

    Ehime, Japan

  • GSK Investigational Site

    Fukuoka, Japan

  • GSK Investigational Site

    Fukuoka, Japan

  • GSK Investigational Site

    Hiroshima, Japan

  • GSK Investigational Site

    Hiroshima, Japan

  • GSK Investigational Site

    Hokkaido, Japan

  • GSK Investigational Site

    Hokkaido, Japan

  • GSK Investigational Site

    Hyōgo, Japan

  • GSK Investigational Site

    Miyagi, Japan

  • GSK Investigational Site

    Nagasaki, Japan

  • GSK Investigational Site

    Nagasaki, Japan

  • GSK Investigational Site

    Okayama, Japan

  • GSK Investigational Site

    Okinawa, Japan

  • GSK Investigational Site

    Tochigi, Japan

  • GSK Investigational Site

    Tokyo, Japan

  • GSK Investigational Site

    Busan, South Korea

Showing 40 of 47 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.